RESUMEN
To understand if international recognized HSE trainings, as NEBOSH, are supporting HSE professionals to harness companies as High Reliability Organizations (HRO) and being resilient towards COVID-19 impacts. The article "Assimilation of HSE standards from different countries - case study" was the previous one published and from which we expect to evolve and understand what can be improved. A survey to HSE professionals such as Health and Safety Managers, Directors and Environmental Managers. On NEBOSH trainings, 65,1% (n=28) professionals answered they feel more prepared to emergent risks (e.g., COVID-19) with this training, 53,5% (n=23) of HSE professionals felt that COVID-19 Pandemic affected their mental health during COVID-19 pandemic, 11,6% (n=5) of professionals resorted to therapy to take care of their mental. Performing Fisher's Exact Test, it was possible to see a significant relationships between Training in Health and Safety Vs Level of improvement of the organization for instance. HSE professionals due to COVID-19 Pandemic felt an impact in their mental health, and some of them had to resort to therapy. This fact makes the situation of mental health more tangible, this because in Portugal for instance, mental health was not very spoken about nor valued.
RESUMEN
OBJECTIVE: To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19. METHODS: We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1ß, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days. RESULTS: Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1ß. CONCLUSION: Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19. TRIAL REGISTRATION NUMBERS: RBR-8jyhxh.